Table 4.
MICs (μg/mL) |
Mutations |
|||||
---|---|---|---|---|---|---|
Dosages (mg/kg) | Danofloxacin | Danofloxacin + reserpine | Enrofloxacin | Enrofloxacin + reserpine | gyrA | parC |
0 | 0.06 | 0.03 | 0.125 | 0.03 | – | – |
0.6 (n = 2) | 0.25 | 0.125 | 0.5 | 0.125 | – | K53E |
0.8 (n = 3) | 0.25 | 0.125 | 0.5 | 0.125 | – | K53E |
1.25 (n = 4) | 1 | 1 | 2 | 1 | S83Y | K53E |
2.5 (n = 3) | 1 | 1 | 2 | 1 | S83Y | K53E |
3.5 (n = 1) | 0.5 | 0.5 | 1 | 0.25 | S83F | K53E |
–, No mutant was found; n, the number of tissue cages with mutant strains; gyrA, parC, the target genes of mutations in QRDRs. Reserpine concentration was at 20 μg/mL.